BLCO

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Alfonso EduardoDirector --15.8k shares Grant / ExerciseMay 26, 2026 $250.0K15.8k shares $15.78 $15.64
Bernier Nathalie D.Director --15.8k shares Grant / ExerciseMay 26, 2026 $250.0K15.8k shares $15.78 $15.64
Collis Steven HDirector --15.8k shares Grant / ExerciseMay 26, 2026 $250.0K15.8k shares $15.78 $15.64
Kavanagh Sarah BDirector --15.8k shares Grant / ExerciseMay 26, 2026 $250.0K15.8k shares $15.78 $15.64
Ling KarenDirector --15.8k shares Grant / ExerciseMay 26, 2026 $250.0K15.8k shares $15.78 $15.64
Paulson JohnDirector --15.8k shares Grant / ExerciseMay 26, 2026 $250.0K15.8k shares $15.78 $15.64

News

seekingalpha.comBausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 9

seekingalpha.comBausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcriptseekingalpha.comJun 1

businesswire.comBausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United Statesbusinesswire.comJun 1

businesswire.comBausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conferencebusinesswire.comMay 21

businesswire.comBausch + Lomb Announces 2026 Annual Meeting of Shareholder Resultsbusinesswire.comMay 20

Trade BLCO

About Bausch + Lomb Corporation

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.

CEO: Brenton L. Saunders
IPO Date: May 6, 2022

Market Data

Open: $15.35
High: $15.77
Low: $15.35
Volume: 398.3K
52W High: $18.92
52W Low: $11.44

Valuation

Market Cap: $5.6B
Enterprise Value: $5.4B

Financials

Free Cash Flow: $-66M
Revenue: $5.1B
Net Income: $-360M
Cash: $383M
Debt: $5.4B

Events

EarningsJul 29

EPS est. 0.16